Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …
Parkinson's disease patients and represents a major limitation for the pharmacological …
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
A Muñoz, Q Li, F Gardoni, E Marcello, C Qin… - Brain: a Journal of …, 2008 - europepmc.org
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …
Parkinson's disease patients and represents a major limitation for the pharmacological …
[引用][C] Combined 5-HTjA and 5-HTjB receptor agonists for the treatment of L-DOPA-induced dyskinesia
A MUNOZ, QIN LI, M CARTA, F GARDONI… - Brain, 2008 - pascal-francis.inist.fr
Combined 5-HTjA and 5-HTjB receptor agonists for the treatment of L-DOPA-induced
dyskinesia CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
dyskinesia CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
A Muñoz, Q Lin, F Gardoni, E Marcello, C Qin… - BRAIN, 2008 - iris.unica.it
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …
Parkinson's disease patients and represents a major limitation for the pharmacological …
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
A Munoz, Q Li, F Gardoni, E Marcello, C Qin… - Brain, 2008 - lup.lub.lu.se
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …
Parkinson's disease patients and represents a major limitation for the pharmacological …
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Q Li, F Gardoni, E Marcello, C Qin… - Brain: A Journal of …, 2008 - search.ebscohost.com
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinsons disease patients and represents a major limitation for the pharmacological …
Parkinsons disease patients and represents a major limitation for the pharmacological …
[引用][C] Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
A Munoz, Q Li, F Gardoni, E Marcello, C Qin… - Brain, 2008 - cir.nii.ac.jp
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
A Munoz, Q Li, F Gardoni, E Marcello, C Qin… - Brain, 2008 - portal.research.lu.se
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …
Parkinson's disease patients and represents a major limitation for the pharmacological …
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
A Muñoz, Q Li, F Gardoni, E Marcello… - Brain: a journal of …, 2008 - pubmed.ncbi.nlm.nih.gov
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …
Parkinson's disease patients and represents a major limitation for the pharmacological …
[引用][C] Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
A MUNOZ - Brain, 2008 - cir.nii.ac.jp
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced
dyskinesia | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
dyskinesia | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …